NDC product
Ultomiris
NDC 25682-022 · Alexion Pharmaceuticals Inc.
Key facts
| Product NDC | 25682-022 |
|---|---|
| Proprietary name | Ultomiris |
| Nonproprietary name | ravulizumab |
| Substances | RAVULIZUMAB |
| Dosage form | SOLUTION, CONCENTRATE |
| Route | INTRAVENOUS |
| Labeler | Alexion Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761108 |
| Pharmacologic classes | Complement Inhibitor [EPC], Complement Inhibitors [MoA] |
| Marketing start | Dec 21, 2018 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: